Potential role of the low-density lipoprotein receptor family as mediators of cellular drug uptake

Advanced Drug Delivery Reviews

Volumn 56, Issue 9, 2004, Pages 1315-1334

  Chung, Nancy S ^a   Wasan, Kishor M ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

ACAT; Acyl CoA: cholesterol O acyltransferase; AmpB; Amphotericin B; Anionic liposomes; APP; Cyclosporine A; LDL receptor gene family; Lipoproteins; Low density lipoprotein receptor; LRP; Megalin; Type 1 ribosome inactivating proteins (RIP)

Indexed keywords

CELL MEMBRANES; CHOLESTEROL; DISEASES; LIPIDS; PHYSIOLOGY; PROTEINS; TISSUE;

LIPOPROTEIN RECEPTORS; LYSOSOMES; PHARMACEUTICAL IMPLICATIONS;

DRUG PRODUCTS;

AMINOGLYCOSIDE; AMPHOTERICIN B; CYCLOSPORIN A; HALOFANTRINE; LIPOSOME; LOW DENSITY LIPOPROTEIN RECEPTOR; NYSTATIN;

CELL SURFACE; CELL TRANSPORT; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; DISEASE COURSE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG UPTAKE; DYSLIPIDEMIA; ENDOCYTOSIS; GRAFT VERSUS HOST REACTION; HUMAN; HYPERTENSION; LIVER TOXICITY; MALARIA; MOLECULAR RECOGNITION; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS;

EID: 1942453793     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2003.12.003     Document Type: Article

References (148)

1. Shephard J., Fruchart J.C. Lipoproteins in health and disease: lipoprotein nomenclature and the classification of hyperlipoproteinemia. Fruchart J.C., Shepard J. Human Plasma Lipoproteins, Clinical Biochemistry: Principles, Methods, Application. vol. 3:1989;1-22 Walter de Gruyter, Berlin.
2. Wasan K.M., Cassidy S.M. Role of plasma lipoproteins in modifying the biological activity of hydrophobic drugs. J. Pharm. Sci. 87:1998;411-423.
3. Davis R.A., Vance J.E. Structure, assembly and secretion of lipoproteins. Vance D.E., Vance J.E. Biochemistry of Lipids, Lipoproteins and Membranes. 1996;473-493 Elsevier, New York.
4. Harmony J.A., Aleson A.L., McCarthy B.M. Lipoprotein structure. Scanu A.M., Spector A.A. Biochemistry and Biology of Plasma Lipoproteins. 1986;403-430 Marcel Dekker, New York.
5. Salter A.M., Brindley D.N. The biochemistry of lipoproteins. J. Inherit. Metab. Dis. 1:1988;4-17.
6. Fielding C.J., Fielding P.E. Molecular physiology of reverse cholesterol transport. J. Lipid Res. 36:1995;211-228.
7. Fielding P.E., Fielding C.J. Dynamics of lipoprotein transport in the human circulatory system. Vance D.E., Vance J.E. Biochemistry of Lipids, Lipoproteins and Membranes. 1996;495-516 Elsevier, New York.
8. Eisenberg S. High-density lipoprotein metabolism. J. Lipid Res. 25:1984;1017-1058.
9. Kuster G.M., Drexel H., Bleisch J.A., Rentsch K., Pei P., Binswanger U., Amann F.W. Relation of cyclosporine blood levels to adverse effects on lipoproteins. Transplantation. 57:1994;1479-1483.
10. Wasan K.M., Lopez-Berestein G. Characteristics of lipid-based formulations that influence their biological behaviour within the plasma of patients. Clin. Infect. Dis. 23:1996;1126-1138.
11. McIntosh M.P., Porter C.J.H., Wasan K.M., Ramaswamy M., Charman W.N. The degree of association of halofantrine with pre- and post-prandial plasma lipoproteins is determined by their apolar lipid content. Pharm. Res. 14:1997;S-277.
12. Awni W.M., Sawchuk R.J. The pharmacokinetics of cyclosporine: blood plasma distribution and binding studies. Drug Metab. Dispos. 13:1984;133-138.
13. Gardier A.M., Mathe D., Guedeney X., Barre J., Benvenutti C., Navarro N., Vernillet L., Loisance D., Cachera J.P., Jacotot B. Effects of plasma lipid levels on blood distribution and pharmacokinetics of cyclosporine A. Ther. Drug Monit. 15:1993;274-280.
14. Sgoutas D., MacMahon W., Love A., Jerkunica I. Interaction of cyclosporine A with human lipoproteins. J. Pharm. Pharmacol. 38:1986;583-588.
15. Hirano T., Akashi T., Oka K., Yoshida M., Matsuno N., Nagao T. Serum cholesterol levels and kidney transplantation outcome: attenuation of cyclosporine efficacy? Transplant. 71:2001;659-660.
16. Wasan K.M., Pritchard P.H., Ramaswamy M., Wong W., Donnachie E.M., Brunner L.J. Differences in lipoprotein lipid concentration and composition modify the plasma distribution of cyclosporine. Pharm. Res. 14:1997;1614-1621.
17. Lemaire M., Pardridge W.M., Chaudhuri G. Influence of blood components on the tissue uptake indices of cyclosporine in rats. J. Pharmacol. Exp. Ther. 244:1988;740-743.
18. Wasan K.M. Modification in plasma lipoprotein concentration and lipid composition regulate the biological activity of hydrophobic drugs. J. Pharmacol. Toxicol. Methods. 36:1996;1-11.
19. Nemunaitis J., Deeg H.J., Yee G.C. Lancet. 1:1986;744-745.
20. De Kippel N., Sennesael J., Lamote J., Ebinger G., de Keyser J. Cyclosporine leukoencephalopathy induced by intravenous lipid solution. Lancet. 339:1992;1114-1115.
21. De Groen P.C., Aksamit A.J., Rakela J., Forbes G.S., Krom R.A. Central nervous system toxicity after liver transplantation. The role of cyclosporine and cholesterol. N. Engl. J. Med. 317:1987;861-866.
22. Pardridge W.M. Carrier-mediated transport of thyroid hormones through the rat blood-brain barrier: primary role of albumin-bound hormone. Endocrinology. 105:1979;605-612.
23. Wasan K.M., Ramaswamy M., Wong W., Pritchard P.H. Lipid transfer protein I facilitated transfer of cyclosporine from low-to high-density lipoproteins is only partially dependent on its cholesteryl ester transfer activity. J. Pharmacol. Exp. Ther. 284:1998;599-605.
24. Wasan K.M., Sivak O. Modifications in lipoprotein surface charge alter cyclosporine A association with low-density lipoproteins. Pharm. Res. 20:2003;126-129.
25. CPS-Compendium of Pharmaceuticals and Specialties 2000.
26. Bennett W.M. Renal effects of cyclosporine. J. Am. Acad. Dermatol. 23:1990;1280-1287.
27. Yee G.C., Salomon D.R. Cyclosporine in applied pharmacokinetics. Evans W.E. Principles of Therapeutic Drug Monitoring. 1992;1-40 Marcel Dekker, New York, NY (USA). Chap. 28.
28. Mihatsch M.J., Thiel G., Ryffel B. Renal side-effects of cyclosporine A with special reference to autoimmune diseases. Br. J. Dermatol. 122:1990;101-115.
29. Gokal R., Mann J.I., Moore R.A., Morris P.J. Hyperlipidemia following renal transplantation. Q. J. Med. 64:1979;634.
30. Raine R.E., Carter R., Mann J.I., Morris P.J. Adverse effect of cyclosporine on plasma cholesterol in renal transplant patients. Nephrol. Dial. Transplant. 3:1988;458-463.
31. Ballantyne C.M., Podet E.J., Patsch W.P., Harati Y., Appel V., Gotto A.M., Young J.B. Effects of cyclosporine therapy on plasma lipoproteins levels. J. Am. Med. Assoc. 262:1989;53-56.
32. Webb A.T., Plant M., Reaveley D.A., O'Donnel M., Luck V.A., O'Connor B., See M., Brown E.A. Lipid and lipoprotein (a) concentrations in renal transplant patients. Nephrol. Dial. Transplant. 7:1992;636-641.
33. Boudreau E.F., Pang L.W., Dixon K.E., Webster H.K., Pavanand K., Tosingha L., Somutsakorn P., Canfield C.J. Malaria: treatment efficacy of halofantrine (WR 171, 699) in initial trials in Thailand. Bull. W.H.O. 66:1988;227-235.
34. Watkins W.M., Lury J.D., Kariuki D., Koech D.K., Oloo J.A., Mosoba M., Mjomba M., Gilles H.M. Efficacy of multiple does-halofantrine in the treatment of chloroquine resistant faciparum malaria in Kenya. Lancet. ii:1988;247-250.
35. Pouvelle B., Spiegel R., Hsiao L., Howard R.J., Morris R.L., Thomas A.P., Taraschi T.F. Direct access to serum macromolecules by intraerythrocytic malaria parasites. Nature. 353:1991;73-75.
36. Grellier P., Rigomier D., Clavey V., Fruchart J., Schrevel J. Lipid traffic between high-density lipoproteins and Plasmodium falciparum-infected red blood cells. J. Cell Biol. 112:1991;267-277.
37. Mohanty S., Mishra S.K., Das B.S., Satpathy S.K., Mohanty D., Patnaik J.K., Bose T.K. Altered plasma lipid pattern in falciparum malaria. Ann. Trop. Med. Parasitol. 86:1992;601-606.
38. Maurois P., Pessah M., Briche I., Alcindor L.G. Alterations in lecithin-cholesterol acyltransferase activity during Plasmodium chabaudi rodent malaria. Biochimie. 67:1985;227-239.
39. Vernes A., Dei Cas E., Dutoit E., Maurois P., Gentilini J.L., Biguet J. Changes of serum lipoproteins during the course of human malaria. J. Pathol. Biol. 28:1980;457-460.
40. Wasan K.M., Ramaswamy M., McIntosh M.P., Porter C.J., Charman W.N. Differences in the lipoprotein distribution of halofantrine are regulated by lipoprotein apolar lipid and protein concentration and lipid transfer protein I activity: in vitro studies in normlipidemic and dyslipidemic human plasmas. J. Pharm. Sci. 88:1999;185-190.
41. McIntosh M.P., Porter C.J., Wasan K.M., Ramaswamy M., Charman W.N. Differences in the lipoprotein binding profile of halofantrine in fed and fasted human or beagle plasma are dictated by the respective masses of core apolare lipoprotein lipid. J. Pharm. Sci. 88:1999;378-384.
42. Brocks D.R., Ramaswamy M., MacInnes A.I., Wasan K.M. The stereoselective distribution of halofantrine enantiomers within human, dog, and rat plasma lipoproteins. Pharm. Res. 17:2000;427-431.
43. Brocks D.R., Wasan K.M. The influence of lipid on stereoselective pharmacokinetics of halofantrine: important implications in food-effect studies involving drugs that bind to lipoproteins. J. Pharm. Sci. 91:2002;1817-1826.
44. Kennedy A.L., Wasan K.M. Preferential distribution of amphotericin B lipid complex into human HDL3 is a consequence of high density lipoprotein coat lipid content. J. Pharm. Sci. 88:1999;1149-1155.
45. Arathoon E.G. Clinical efficacy of echinocandin antifungals. Curr. Opin. Infect. Dis. 14:2001;685-691.
46. Barwics J., Gruda I., Tancr P. A kinetic study of the oxidation effects of amphotericin B on human low-density lipoproteins. FEBS Lett. 465:2000;83-86.
47. Hartsel S.C., Baas B., Bauer E., Foree L.D. Jr., Kindt K., Preis H., Scott A., Kwong E.H., Ramaswamy M., Wasan K.M. Heat-induced superaggregation of amphotericin B modifies its interaction with serum proteins and lipoproteins and stimulation of TNF-alpha. J. Pharm. Sci. 90:2001;124-133.
48. Ramaswamy M., Peteherych K.D., Kennedy A.L., Wasan K.M. Amphotericin B lipid complex or amphotericin B multiple-dose administration to rabbits with elevated plasma cholesterol levels: pharmacokinetics in plasma and blood, plasma lipoprotein levels, distribution in tissues, and renal toxicities. Antimicrob. Agents Chemother. 45:2001;1184-1191.
49. Medoff G., Brajtburg J., Kobayashi G.S. Antifungal agents useful in therapy of systemic fungal infections. Annu. Rev. Pharmacol. Toxicol. 23:1983;303-313.
50. Cassidy S.M., Strobel F.W., Wasan K.M. Plasma lipoprotein distribution of liposomal nystatin is influenced by protein content of high-density lipoproteins. Antimicrob. Agents Chemother. 42:1998;1878-1888.
51. Wasan K.M., Ramaswamy M., Cassidy S.M., Kazemi M., Strobel F.W., Thies R.L. Physical characterisitics and lipoprotein distribution of liposomal nystatin in human plasma. Antimicrob. Agents Chemother. 41:1997;1871-1875.
52. Ramaswamy M., Wallace T.L., Cossum P.A., Wasan K.M. Species differences in the proportion of plasma lipoprotein lipid carried by high-density lipoproteins influence the distribution of free and liposomal nystatin in human, dog and rat plasma. Antimicrob. Agents Chemother. 43:1999;1424-1428.
53. Nykjaier A., Willnow T.E. The low-density lipoprotein receptor gene family: a cellular Swiss army knife? Trends Cell Biol. 12:2002;273-280.
54. Willnow T.E., Nykjaier A., Herz J. Lipoprotein receptors: new roles for ancient proteins. Nat. Cell Biol. 1:1999;E157-E162.
55. Brown M.S., Goldstein J.L. A receptor-mediated pathway for cholesterol homeostasis. Science. 232:1986;34-47.
56. Goldstein J.L., Hobbs H.H., Brown M.S. Scriver C.S., Baendet A.L., Sly W.S., Valle D. The Metabolic and Molecular Basis of Inherited Disease. 1995;1981-2030 McGraw-Hill, New York.
57. Hussain M.M., Strickland D.K., Bakillah A. The mammalian low-density lipoprotein receptor family. Annu. Rev. Nutr. 19:1999;141-172.
58. Yamamoto T., Davis C.G., Brown M.S., Schneider W.J., Casey M.L., Goldstein J.L., Russell D.W. The human LDL receptor: a cysteine-rich protein with multiple alu sequences in its mRNA. Cell. 39:1984;27-38.
59. Gliemann J. Receptors of the low density lipoprotein (LDL) receptor family in man: multiple functions of the large family members via interaction with complex ligands. Biol. Chem. 379:1998;951-964.
60. Takahashi S., Kawarabayashi Y., Nakai T., Sakai J., Yamamoto T. Rabbit very low density lipoprotein receptor: a low density lipoprotein receptor-like protein with distinct ligand specificity. Proc. Natl. Acad. Sci. U. S. A. 89:1992;9252-9256.
61. Jingami H., Yamamoto T. The VLDL receptor: wayward brother of the LDL receptor. Curr. Opin. Lipidol. 6:1995;104-108.
62. Yamamoto T., Bujo H. Close encounter with apolipoprotein E receptors. Curr. Opin. Lipidol. 7:1996;298-302.
63. Yamamoto T., Takahashi S., Sakai J., Kawarabayasi Y. The very low density lipoprotein receptor: a second lipoprotein receptor that may mediate uptake of fatty acids into muscle and fat cells. Trends Cardiovasc. Med. 3:1993;144-148.
64. Maulthaupt H.A., Gafvels M.E., Kariko K., Jin H., Arenas-Elliot C., Godlman B.I., Strauss J.F., Angelin B., Warhol M.J., McCrae K.R. Expression of very low-density lipoprotein receptor in the vascular wall: analysis of human tissues by in situ hybridization and immunohistochemistry. Am. J. Pathol. 148:1996;1985-1997.
65. Frykman P.K., Brown M.S., Yamamoto T., Goldstein J.L., Herz J. Normal plasma lipoproteins and fertility in gene-targeted mice homozygous for a disruption in the gene encoding very low density lipoprotein receptor. Proc. Natl. Acad. Sci. U. S. A. 92:1995;8453-8457.
66. Heegaard C.W., Simonsen A.C., Oka K., Kjoller L., Christensen A., Madsen B., Ellgaard L., Chan L., Andreasen P.A. Very low density lipoprotein receptor binds and mediates endocytosis of urokinase-type plasminogen activator-type-1 plasminogen activator inhibitor complex. J. Biol. Chem. 270:1995;20855-20861.
67. Hussain M.M. Structural, biochemical and signaling properties of the low-density lipoprotein receptor gene family. Front. Biosci. 6:2001;417-428.
68. Kim D.H., Iijima H., Goto K., Sakai J., Ishii H., Kim H.J., Suzuki H., Kondo H., Saiki S., Yamamoto T. Human apolipoprotein E receptor 2: a novel lipoprotein receptor of the low density lipoprotein receptor family predominantly expressed in the brain. J. Biol. Chem. 271:1996;8373-8380.
69. Novak S., Heisberger T., Schneider W.J., Nimpf J. A new low-density lipoprotein receptor homologue with 8 ligand binding repeats in brain of chicken and mouse. J. Biol. Chem. 271:1996;11732-11736.
70. Curran T., D'Arcangelo G. Role of reelin in the control of brain development. Brain Res. Brain Res. Rev. 26:1998;285-294.
71. Trommsdorff M., Gotthardt M., Hiesberger T., Shelton J., Stockinger W., Nimpf J., Hammer R.E., Richardson J.A., Herz J. Reeler/disabled-like disruption of neuronal migration in knockout mice lacking the VLDL receptor and apoE receptor 2. Cell. 97:1999;689-701.
72. Herz J. The LDL receptor gene family: (un)expected signal transducers in the brain. Neuron. 29:2001;571-581.
73. Neels J.G., van Den Berg B.M., Lookene A., Olivecrona G., Pannekock H., van Zonneveld A.J. The second and fourth cluster of class A cysteine-rich repeats of the low density lipoprotein receptor-related protein share ligand-binding properties. J. Biol. Chem. 274:1999;31305-31311.
74. Webb J.C., Patel D.D., Jones M.D., Knight B.L., Soutar A.K. Characterization and tissue-specific expression of the human 'very low density lipoprotein (VLDL) receptor' mRNA. Hum. Mol. Genet. 3:1994;531-537.
75. Liu C.X., Musco S., Lisitsina N.M., Forgacs E., Minna J.D., Lisitsyn N.A. LRP-DIT, a putative endocytic receptor gene is frequently inactivated in non-small cell lung cancer cell lines. Cancer Res. 60:2000;1961-1967.
76. Liu C.X., Li Y., Obermoeller-McCormick L.M., Schwartz A.L., Bu G. The putative tumor suppressor LRP1b, a novel member of the low-density lipoprotein (LDL) receptor family, exhibits both overlapping and distinct properties with the LDL receptor-related protein. J. Biol. Chem. 276:2001;28889-28896.
77. Li Y., Knisely J.M., Lu W., McCormick L.M., Wang J., Henkin J., Schwartz A.L., Bu G. Low density lipoprotein (LDL) receptor-related protein 1b impairs urokinase receptor regeneration on the cell surface and inhibits cell migration. J. Biol. Chem. 277:2002;42366-42371.
78. Adams M.D., Celniker S.E., Holt R.A., Evans C.A., Gocayne J.D., Amanatides P.G., Scherer S.E., Li P.W., Hoskins R.A. The genome sequence of Drosophila melanogaster. Science. 287:2000;2185-2195.
79. Nakayama M., Nakajima D., Nagase T., Nomura N., Seki N., Ohara O. Identification of high-molecular-weight proteins with multiple EGF-like motifs by motif-trap screening. Genomics. 51:1998;27-34.
80. Brown S.D., Twells R.C., Hey P.J., Cox R.D., Levy E.R., Soderman A.R., Metzker M.L., Caskey C.T., Todd J.A., Hess J.F. Isolation and characterization of LRP6, a novel member of the low density lipoprotein receptor gene family. Biochem. Biophys. Res. Commun. 248:1998;879-888.
81. Dong Y., Lathrop W., Weaver D., Qui Q., Cini J., Bertolini D., Chen D. Molecular cloning and characterization of LR3, a novel LDL receptor family protein with mitogenic activity. Biochem. Biophys. Res. Commun. 251:1998;784-790.
82. Hey P.J., Twells R.C., Phillips M.S., Yusuke N., Brown S.D., Kawaguchi Y., Cox R., Guochun X., Dugan V., Hammond H., Metzker M.L., Todd J.A., Hess J.F. Cloning of a novel member of the low-density lipoprotein receptor family. Gene. 216:1998;103-111.
83. Pinson K.I., Brennan J., Monkley S., Avery B.J., Skarnes W.C. An LDL receptor-related protein mediates Wnt signaling in mice. Nature. 407:2000;535-538.
84. Tamai K., Semenov M., Kato Y., Spokony R., Liu C., Katsuyama Y., Hess F., Saint-Jeannet J.P., He X. LDL receptor-related proteins in Wnt signal transduction. Nature. 407:2000;530-535.
85. Wehrli M., Dougan S.T., Caldwell K., O'Keefe L., Schwartz S., Vaizel-Ohayon D., Schejter E., Tomlinson A., DiNardo S. Arrow encodes an LDL-receptor-related protein essential for wingless signaling. Nature. 407:2000;527-530.
86. Tolwinski N.S., Wehrli M., Rives A., Erdeniz N., DiNardo S., Wieschaus E. Wg/Wnt signal can be transmitted through arrow/LRP5,6 and axin independently of Zw3/Gsk3beta activity. Dev. Cell. 4:2003;407-418.
87. Mao J., Wang J., Liu B., Pan W., Farr G.H. III, Flynn C., Yuan H., Takada S., Kimelman D., Li L., Wu D. Low-density lipoprotein receptor-related protein-5 binds to Axin and regulates the canonical Wnt signaling pathway. Mol. Cell. 7:2001;801-809.
88. Gong Y., Slee R.B., Fukai N., Rawadi G., Roman-Roman S., Reginato A.M., Wang H., Cundy T., Glorieux F.H., Lev D., Zacharin M., Oexle K.et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell. 107:2001;513-523.
89. Van Wesenbeeck L., Cleiren E., Gram J., Beals R.K., Benichou O., Scopelliti D., Key L., Renton T., Bartels C., Gong Y., Warman M.L., De Vernejoul M.C., Bollerslev J., Van Hul W. Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density. Am. J. Hum. Genet. 72:2003;763-771.
90. Hsieh J.C., Lee L., Zhang L., Wefer S., Brown K., DeRossi C., Wines M.E., Rosenquist T., Holdener B.C. Mesd encodes and LRP5/6 chaperone essential for specification of mouse embryonic polarity. Cell. 112:2003;355-367.
91. Jacobsen L., Madsen P., Moestrup S.K., Lund A.H., Tommerup N., Nykjaer A., Sottrup-Jensen L., Gliemann J., Petersen C.M. Molecular characterization of a novel human hybrid-type receptor that binds the alpha2-macroglobulin receptor-associated protein. J. Biol. Chem. 271:1996;31379-31383.
92. Yamazaki H., Bujo H., Kusunokoi J., Seimiya K., Kanaki T., Morisaki N., Schneider W.J., Saito Y. Elements of neural adhesion molecules and a yeast vacuolar protein sorting receptor are present in a novel mammalian low density lipoprotein receptor family member. J. Biol. Chem. 271:1996;247651-247668.
93. Morwald S., Yamazaki H., Bujo H., Kusunoli J., Kanaki T., Seimiya K., Morisaki N., Nimpf J., Schneider W.J., Saito Y. A novel mosaic protein containing LDL receptor elements is highly conserved in humans and chicken. Arterioscler. Thromb. Vasc. Biol. 17:1997;996-1002.
94. Riedel I.B., Hermans-Borgmeyer I., Hubner C.A. SorLa, a member of the LDL receptor family is expressed in the collecting duct of the murine kidney. Histochem. Cell Biol. 118:2002;183-191.
95. Hampe W., Urny J., Franke I., Hoffmeister-Ullerich S.A., Herrmann D., Petersen C.M., Lohmann J., Schaller H.C. A head-activator binding protein is present in hydra in a soluble and a membrane-anchored form. Development. 126:1999;4077-4086.
96. Hampe W., Hermans-Borgmeyer I., Shaller H.C. Function of the neuropeptide head activator for early neural and neuroendocrine development. Results Probl. Cell Differ. 26:1999;323-337.
97. Hampe W., Riedel I.B., Lintzel J., Bader C.O., Franke I., Schaller H.C. Ectodomain shedding, translocation and synthesis of SorLA are stimulated by its ligand head activator. J. Cell. Sci. 113:2000;4475-4485.
98. Hirayama S., Bujo H., Yamazaki H., Kanaki T., Takahashi K., Kobayashi J., Schneider W.J., Saito Y. Differentail exression of LR11 during proliferation and differentiation of cultured neuroblastoma cells. Biochem. Biophys. Res. Commun. 275:2000;365-373.
99. Kanaki T., Bujo H., Hirayama S., Ishii I., Morisaki N., Schneider W.J., Saito Y. Expression of LR11, a mosaic LDL receptor family member, is markedly increased in atherosclerotic lesions. Arterioscler. Thromb. Vasc. Biol. 19:1999;2687-2695.
100. Yamazaki H., Bujo H., Kusunoki J., Seimiya K., Kanaki T., Morisaki N., Schneider W.J., Saito Y. Elements of neural adhesion molecules and a yeast vacuolar protein sorting receptor are present in a novel mammalian low density lipoprotein receptor family member. J. Biol. Chem. 271:1996;24761-24768.
101. Taira K., Bujo H., Hirayama S., Yamazaki H., Kanaki T., Takahashi K., Ishii I., Miida T., Schneider W.J., Saito Y. LR11, a mosaic LDL receptor family member, mediates the uptake of ApoE-rich lipoproteins in vitro. Arterioscler. Thromb. Vasc. Biol. 21:2001;1501-1506.
102. Zhu Y., Bujo H., Yamazaki H., Hirayama S., Kanaki T., Takahashi K., Shibasaki M., Schneider W.J., Saito Y. Enhanced expression of the LDL receptor family member LR11 increases migration of smooth muscle cells in vitro. Circulation. 105:2002;1830-1836.
103. Lintzel J., Franke I., Riedel I.B., Schaller H.C., Hampe W. Characterization of the VPS10 domain of SorLa/LR11 as binding site for the neuropeptide HA. Biol. Chem. 383:2002;1727-1733.
104. Kanaki T., Bujo H., Hirayama S., Tanaka K., Yamazaki H., Seimiya K., Morisaki N., Schneider W.J., Saito Y. Developmental regulation of LR11 expression in murine brain. DNA Cell Biol. 17:1998;647-657.
105. Herz J., Hamann U., Rogne S., Myklebost O., Gausepohl H., Stanley K.K. Surface location and high affinity for calcium of 600 kd liver membrane protein closely related to the LDL-receptor suggest a physiological role as lipoprotein receptor. EMBO J. 7:1988;4119-41127.
106. Beisiegel U., Weber W., Ihrke G., Herz J., Stanley K.K. The LDL-receptor-related protein, LRP, is an apolipoprotein E-binding protein. Nature. 341:1989;162-164.
107. Kowal R.C., Herz J., Goldstein J.L., Esser V., Brown M.S. Low density lipoprotein receptor-related protein mediates uptake of cholesteryl esters derived from apoprotein E-enriched lipoproteins. Proc. Natl. Acad. Sci. U. S. A. 86:1989;5810-5814.
108. Moestrup S.K., Gliemann J., Pallesen G. Distribution of the alpha 2-macroglobulin/low density lipoprotein receptor-related protein in human tissues. Cell Tissue Res. 269:1992;375-382.
109. Beisiegel U., Weber W., Bengtsson-Olivecrona G. Lipoprotein lipase enhances the binding of chylomicrons to low density lipoprotein receptor-related protein. Proc. Natl. Acad. Sci. U. S. A. 88:1991;8342-8346.
110. Herz J., Clouthier D.E., Hammer R.E. LDL receptor-related protein internalizes and degrades uPA-PAI-1 complexes and is essential for embryo implantation. Cell. 71:1992;411-421. (Erratum in: Cell 73 (1993), 428).
111. Rohlmnn A., Gotthardt M., Hammer R.E., Herz J. Inducible inactivation of hepatic LRP gene by cre-mediated recombination confirms the role of LRP in clearance of chylomicron remnants. J. Clin. Invest. 101:1998;689-695.
112. Kristensen T., Moestrup S.K., Gliemann J., Bendtsen L., Sand O., Sottrup-Jensen L. Evidence that the newly cloned low-density lipoprotein receptor related protein (LRP) is the. FEBS Lett. 276:1990;151-155.
113. 2-macroglobulin receptor and low density lipoprotein receptor-related protein suggests that this protein is multifunctional receptor. J. Biol. Chem. 265:1990;17401-17404.
114. Nykjaer A., Bengtsson-Olivecrona G., Lookene A., Moestrup S.K., Petersen C.M., Weber W., Beisiegel U., Gliemann J. The alpha 2-macroglobulin receptor/low density lipoprotein receptor-related protein binds lipoprotein lipase and beta-migrating very low density lipoprotein associated with the lipase. J. Biol. Chem. 268:1993;15048-15055.
115. Kang D.E., Saitoh T., Chen X., Xia Y., Masliah E., Hansen L.A., Thomas R.G., Thal L.J., Katzman R. Genetic association of the low-density lipoprotein receptor-related protein gene (LRP), an apolipoprotein E receptor, with late-onset Alzheimer's disease. Neurology. 49:1997;56-61.
116. Lambert J.C., Wavrant-De Vrieze F., Amouyel P., Charteir-Harlin M.C. Association of LRP gene locus with sporadic late-onset Alzheimer's disease. Lancet. 351:1998;1787-1788.
117. Wavrant-De Vrieze F., Perez-Tur J., Lambert J.C., Frigard B., Pasquier F., Delacourte A., Amouyel P., Hardy J., Chartier-Harlin M.C. Association between the low density lipoprotein receptor-related protein (LRP) and Alzheimer's disease. Neurosci. Lett. 227:1997;68-70.
118. Herz J., Beffert U. Apolipoprotein E receptors, linking brain development and Alzheimer's disease. Nat. Rev., Neurosci. 1:2000;51-58.
119. Wasan K.M., Subramanian R., Chou J.W., Ramaswamy M., Pritchard P.H. Cyclosporine transfer from low-and high-density lipoproteins is partially influenced by lipid transfer protein I triglyceride transfer activity. Pharm. Res. 16:1999;1067-1073.
120. Kwong M., Sivak O., Kwong E.H., Wasan K.M. Cyclosporine A transfer between high-and low-density lipoproteins: independent from lipid transfer protein I-facilitated transfer of lipoprotein-coated phospholipids because of high affinity of cyclosporine A for the protein component of lipoprotein. J. Pharm. Sci. 90:2001;1308-1317.
121. Kerjaschki D., Farquhar M.G. Immunocytochemical localization of Heymann nephritis antigen (GP330) in glomerular epithelial cells of normal Lewis rats. J. Exp. Med. 157:1983;667.
122. Leheste J., Rolinski B., Vorum H., Hipert J., Nykjaier A., Jacobsen C., Aucouturier P., Moskaug J.O., Otto A., Christensen E.I., Willnow T.E. Megalin knockout mice as an animal model of low molecular weight proteinuria. Am. J. Pathol. 155:1999;1361-1370.
123. Willnow T.E. The low-density lipoprotein receptor gene family: multiple roles in lipid metabolism. J. Mol. Med. 77:1999;306-315.
124. Schmitz C., Hipert J., Jacobsen C., Boensch C., Christensen E.I., Luft F.C., Willnow T.E. Megalin deficiency offers protection from renal aminoglycoside accumulation. J. Biol.Chem. 277:2002;618-622.
125. Moestrup S.K., Cui S., Vorum H., Bregengard C., Bjorn S.E., Norris K., Gliemann J., Christensen E.I. Evidence that epithelial glycoprotein 330/megalin mediates uptake of polybasic drugs. J. Clin. Invest. 96:1995;1404-1413.
126. Farquhar M.G. The unfolding story of megalin (gp330): now recognized as a drug receptor. J. Clin. Invest. 96:1995;1184.
127. Nagai J., Tanaka H., Nakanishi N., Murakami T., Takano M. Role of megalin in renal handling of aminoglycosides. Am. J. Physiol., Renal. Physiol. 281:2001;F334-F337.
128. Saito A., Pietromonaco S., Loo A.K.C., Farquhar M.G. Complete cloning and sequencing of rat gp330/"megalin", a distinctive member of the low density lipoprotein receptor gene family. Proc. Natl. Acad. Sci. U. S. A. 91:1994;9725-9729.
129. Stefansson S., Chappell D.A., Argraves K.M., Strickland D.K., Argraves W.S. Glycoprotein 330/low density lipoprotein receptor-related protein-2 mediates endocytosis of low density lipoproteins via interaction with apolipoprotein B100. J. Biol. Chem. 270:1995;19417-19421.
130. Orlando R.A., Exner M., Czekay R.P., Yamazaki H., Saito A., Ullrich R., Kerjaschki D., Farquhar M.G. Identification of the second cluster of ligand-binding repeats in megalin as a site for receptor-ligand interactions. Proc. Natl. Acad. Sci. U. S. A. 94:1997;2368-2373.
131. Zheng G., Bachinsky D.R., Stamenkovic I., Strickland D.K., Brown D. Organ distribution in rats of two members of the low-density lipoprotein receptor gene family, gp330 and LRP/alpha 2MR, the receptor-associated protein (RAP). J. Histochem. Cytochem. 42:1994;531-542.
132. Chan W.L., Shaw P.C., Tam S.C., Jacobsen C., Gliemann J., Nielsen M.S. Trichosanthin interacts with and enters cells via LDL receptor family members. Biochem. Biophys. Res. Commun. 270:2000;453-457.
133. Cavallaro U., Nykjaier A., Nielsen M., Soria M.R. Alpha 2-macroglobulin receptor mediates binding and cytotoxicity of plant ribosome-inactivating proteins. Eur. J. Biochem. 232:1995;165-171.
134. Amin K., Wasan K.M., Albrecht R.M., Heath T.D. Cell association of liposomes with high fluid anionic phospholipids content is mediated specifically by the LDL and its receptor. J. Pharm. Sci. 91:2002;1233-1244.
135. Amin K., Ng K., Brown C.S., Bruno M.S., Heath T.D. LDL induced association of anionic liposomes with cells and delivery of contents as shown by the increase in potency of liposome dependent drugs. Pharm. Res. 18:2001;914-921.
136. Amin K., Heath T.D. LDL-induced association of anionic liposomes with cells and delivery of contents: II. Interaction of liposomes with cells in serum-containing medium. J. Control. Release. 73:2001;49-57.
137. Lakkaraju A., Rahman Y., Dubinsky J.M. Low-density lipoprotein-related protein mediates the endocytosis of anionic liposomes in neurons. J. Biol. Chem. 277:2002;15085-15092.
138. Rensen P.C.N., Schiffelers R.M., Versluis A.J., Bijsterbosch M.K., Van Kuijk-Meuwissen M.E.M.J., Van Berkel T.J.C. Human recombinant apolipoprotein E-enriched liposomes can mimic low-density lipoproteins as carriers for site-specific delivery of antitumor agents. Mol. Pharmacol. 52:1997;445-455.
139. Versluis A.J., Rump E.T., Rensen P.C., Van Berkel T.J., Bijsterbosch M.K. Synthesis of a lipophilic daunorubicin derivative and its incorporation into lipidic carriers developed for LDL receptor-mediated tumor therapy. Pharm. Res. 15:1998;531-537.
140. Versluis A.J., Rensen P.C., Rump E.T., Van Berkel T.J., Bijsterbosch M.K. Low-density lipoprotein receptor-mediated delivery of a lipophilic daunorubicin derivative to B16 tumours in mice using apolipoprotein E-enriched liposomes. Br. J. Cancer. 78:1998;1607-1614.
141. Versluis A.J., Rump E.T., Rensen P.C.N., Van Berkel T.J.C., Bijsterbosch M.K. Stable incorporation of lipophilic daunorubicin prodrug into apolipoprotein E-exposing liposomes induces uptake of prodrug via low-density lipoprotein receptor in vivo. J. Pharmacol. Exp. Ther. 289:1999;1-7.
142. 4-octadecyl-1-β-D-arabinofuranosylcytosine, a new anticancer drug. J. Pharmacol. Exp. Ther. 282:1997;1572-1580.
143. 4-octadecyl-1- β-D-arabinofuranosylcytosine in Daudi lymphoma cells. Br. J. Cancer. 80:1999;1542-1549.
144. Rodrigues D.G., Covolan C.C., Coradi S.T., Barboza R., Maranhao R.C. Use of a cholesterol-rich emulsion that binds to low-density lipoprotein receptors as a vehicle for paclitaxel. J. Pharm. Pharmacol. 54:2002;765-772.
145. Hirano T., Akashi T., Oka K., Yoshida M., Matsuno N., Nagao T. Serum cholesterol levels and kidney transplantation outcome: attenuation of cyclosporine efficacy? Transplant. 71:2001;659-660.
146. Strong M.L., Ueda C.T. Effects of low and high density lipoproteins on renal cyclosporine A and cyclosporine G disposition in the isolated perfused rat kidney. Pharm. Res. 14:1997;1466-1471.
147. Peteherych K.D., Wasan K.M. Effects of plasma lipoproteins on cyclosporine A toxicity and uptake in LLCPK1 pig kidney cell. J. Pharm. Sci. 90:2001;1395-1406.
148. Wasan K.M., Donnachie E.M., Seccombe D.W., Pritchard P.H. Effect of cyclosporine A on the binding affinity and internalization of low-density lipoproteins in human skin fibroblasts. J. Pharm. Sci. 91:2002;2520-2524.